ClinicalTrials.gg
RecruitingNCT05477979Updated Feb 25, 2025

The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)

An observational study in Lung Cancer, Psychological Stress and Immune Checkpoint Inhibitors, sponsored by Second Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Second Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
82nd of 259
750 · median 307
Started
2020
with 44 others
Observational
259 of 850
114 open now
Primary completion
2027-12
later than 302 of 422 live
Registered
412th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 82nd largest by planned enrollment of the 259 observational ones that give a count, is one of 45 that started in 2020, is one of 259 observational ones, reaches primary completion later than 302 of the 422 other live ones, and was the 412th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.

Read the detailed description

This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of ICIs and prognosis of Lung Cancer. This study will have 4 cohorts

  • Cohort 1 (STRESS-LUNG-1): A prospective, observational cohort study to explore the association between psychological stress and the efficacy of first-line treatment of ICIs in advanced NSCLC.
  • Cohort 2 (STRESS-LUNG-2): A prospective, observational cohort study to explore the association between psychological stress and the efficacy of first-line treatment of limited-stage and extensive-stage SCLC.
  • Cohort 3 (STRESS-LUNG-3): A prospective, observational cohort study to explore the association between psychological stress and the efficacy of neoadjuvant therapy of ICIs in resectable NSCLC.
  • Cohort 4 (STRESS-LUNG-4): A prospective, observational cohort study to explore the association of psychological stress with cancer progression, and Prognosis in early-stage NSCLC receiving radical surgery.
03

Conditions studied

  • Lung Cancer
  • Psychological Stress
  • Immune Checkpoint Inhibitors
  • Cancer, Treatment-Related

Keywords

  • Lung cancer
  • Immune checkpoint inhibitors
  • Psychological stress
  • Cancer progression
  • Prognosis
  • Biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.

Eligibility criteria

Cohort 1 (STRESS-LUNG-1):

Inclusion Criteria:

  1. Age ≥ 18 years;
  2. confirmed diagnosis of NSCLC;
  3. Unresectable locally advanced, , or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  4. (ECOG) performance status of 0-1;
  5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  6. Presence of at least one according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 ( v1.1) ;
  7. Receiving /PD-L1 inhibitors monotherapy or combination with chemotherapy;
  8. Informed and agreed to participate in the study;

Exclusion Criteria:

  1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  2. Combined with other malignant tumors in the past 3 years;
  3. Concurrent acute or chronic psychiatric disorders;
  4. Current receiving anti-depressive or anti-anxiety therapy;
  5. Previous treatment with other clinical drug trials;
  6. Patients with symptomatic ;
  7. Can't cooperate with psychological scale assessment;

Cohort 2 (STRESS-LUNG-2):

  1. Age ≥ 18 years;
  2. Pathologically diagnosed as small cell lung cancer;
  3. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;
  7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  8. Informed and agreed to participate in the study;

Exclusion Criteria:

  1. Combined with other malignant tumors in the past 3 years;
  2. Concurrent acute or chronic psychiatric disorders;
  3. Current receiving anti-depressive or anti-anxiety therapy;
  4. Previous treatment with other clinical drug trials;
  5. Patients with symptomatic brain metastasis;
  6. Can't cooperate with psychological scale assessment;

Cohort 3 (STRESS-LUNG-3):

  1. Age ≥18 years ;
  2. Pathologically diagnosed as non-small cell lung cancer;
  3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;
  4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard;
  5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  6. Receiving PD-1/PD-L1 inhibitors combined with chemotherapy as therapy.
  1. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study;

Exclusion Criteria:

  1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  2. Combined with other malignant tumors in the past 3 years;
  3. Concurrent acute or chronic psychiatric disorders;
  4. Current receiving anti-depressive or anti-anxiety therapy;
  5. Previous treatment with other clinical drug trials;
  6. Can't cooperate with psychological scale assessment;

Cohort 4 (STRESS-LUNG-4):

  1. Age ≥18 years;
  2. Pathologically diagnosed as non-small-cell lung cancer;
  3. Pathologically stage conformed as early stage of IA-IIIA
  4. Available for tumor tissue samples;
  5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  6. Receiving radical surgery;
  7. Informed and agreed to participate in the study;

Exclusion Criteria:

  1. Combined with other malignant tumors in the past 3 years;
  2. Concurrent acute or chronic psychiatric disorders;
  3. Current receiving anti-depressive or anti-anxiety therapy;
  4. Previous treatment with other clinical drug trials;
  5. Can't cooperate with psychological scale assessment;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Cohort 1: advanced NSCLC patients receiving first-line ICIs (STRESS-LUNG-1 study)

    For stage IIIB-IV patients with NSCLC who have received immune checkpoint inhibitors as first-line therapy.

    Other: Exposure: psychological stress status

  • Cohort 2: limited-stage and extensive-stage SCLC patients receiving ICIs (STRESS-LUNG-2 study)

    For limited-stage and extensive-stage SCLC patients who have received immune checkpoint inhibitors

    Other: Exposure: psychological stress status

  • Cohort 3: NSCLC patients receive neoadjuvant therapy of ICIs(STRESS-LUNG-3 study)

    For stage IB-IIIB patients with non-small cell lung cancer who have received neoadjuvant therapy of immune checkpoint inhibitors.

    Other: Exposure: psychological stress status

  • Cohort 4: NSCLC patients receive radical resection (STRESS-LUNG-4 study))

    For early-stage patients with non-small cell lung cancer who have received radical resection.

    Other: Exposure: psychological stress status

Interventions

  • OtherExposure: psychological stress status

    The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

06

What researchers measure

Primary outcomes

  1. Cohort 1 & 2: Progression-free survival (PFS)

    Time from the beginning of first-line immunotherapy to the first progression (PD) in patients with lung cancer

    Time frame: 3 years

  2. Cohort 3: Pathologic complete response (pCR) rate

    pCR is no viable tumor cells in tumor bed and lymph nodes. The pCR rate is the proportion of patients with a pathologic complete response.

    Time frame: 3 years

  3. Cohort 4: Disease-free survival (DFS)

    The duration between the date after surgery to the date of any recurrence or death firstly

    Time frame: 5 years

Secondary outcomes

  1. Overall survival (OS)

    Overall survival (OS) is defined as the duration from the beginning of first-line immunotherapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.

    Time frame: 5 years

  2. Quality of life

    Quality of life (QoL) is assessed longitude by Short Form Health Survey 36 (SF-36) and EORTC QLQ-C30 (version.3). SF-36 includes 36 items and assesses the functional status and well-being on eight multi-item subscales. The total score on each SF-36 subscale ranges between 0 and 100. A greater score indicates better QoL. The EORTC QLQ-C30 is composed of 9 multi-item scales: 5 functioning scales (physical, role, cognitive, emotional, and social), a global QOL scale, and 3 symptom scales (fatigue, pain, and nausea/vomiting). All scales and single items are linearly transformed to an 0-100 scale. A higher score represents a better level of functioning.

    Time frame: 5 years

  3. Objective Response Rate (ORR)

    The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: 2 years

Other outcomes

  1. The correlation between gut microbiota and chronic stress and the efficacy of ICIs

    The baseline fetal is collected and assessed by 16S rRNA sequencing. And explore the association between gut microbiota and chronic stress and the efficacy of ICIs during the enrolled observation process.

    Time frame: 5 years

  2. The correlation between tumor microenvironment signature and chronic stress and the efficacy of ICIs

    The baseline paraffin-embedded tissue is collected and assessed by multiplex immunohistochemistry, including T lymphocytes, B lymphocytes, NK lymphocytes, macrophagocyte, and DC cells. And explore the association between tumor microenvironment signature and chronic stress and the efficacy of ICIs during the enrolled observation process.

    Time frame: 5 years

  3. The correlation between peripheral stress biomarker and immune cells signature and chronic stress and the efficacy of ICIs

    The baseline peripheral venous blood is collected. The stress biomarkers including epinephrine, norepinephrine, cortisol and ACTH. The peripheral immune cells signature and assessed by flow cytometry, including T lymphocytes, B lymphocytes, NK lymphocytes, macrophagocyte, and DC cells.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2027, 90 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 90 months is above that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2022
First posted
Jul 28, 2022
StartActual
Jun 1, 2020
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05477979
Lead sponsor
Second Xiangya Hospital of Central South University
Responsible party
Fang Wu (Professor, Central South University) — Principal investigator
First posted
Jul 28, 2022
Start date
Jun 1, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 25, 2025

Study contacts

Fang Wu, MD. PhD
Contact
wufang4461@csu.edu.cn
+86 13574858332

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion